Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients
myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and…
Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy
myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL…
Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies
myCare-021-02 study discovers patient-specific resistance mechanisms that can inform…
Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with
Monosomy 7
myCare-021-04 study finds genetic signatures associated with 100% remission rate from AML…